Soligenix preclinical data

Soligenix said VeloThrax in combination with ThermoVax vaccine thermostabilization technology retained its potency and structural integrity when exposed to temperatures of up to 70 degrees Celsius for >=1 month. Additionally, VeloThrax in combination with ThermoVax and a secondary adjuvant led to rapid onset of antibodies that correlated to protection against anthrax in animal models. The company said ThermoVax combines lyophilization technology, which removes water from pharmaceutical preparations, with aluminum adjuvants, secondary adjuvants and protein subunits to produce stable and potent vaccine formulations. VeloThrax, a translocation-deficient mutant recombinant protective antigen (rPA) anthrax vaccine, is being developed under FDA's Animal Rule, which allows marketing approval to be granted based on efficacy in relevant animal models and an acceptable safety risk profile in humans. ...